Cerus Corporation announced it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. The agreement covers Cerus' entire INTERCEPT product line, which includes pathogen reduction technology for platelets, plasma, and the INTERCEPT Fibrinogen Complex (IFC). The arrangement is designed to expand access to these products among BCA's 60+ member blood centers, which collectively produce about half of the U.S. platelet and cryoprecipitate supply. The agreement also includes a resource-sharing model to facilitate production and distribution of IFC, as well as collaborative training and education initiatives to increase awareness and adoption of pathogen reduction technologies.